Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...

Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 2024 financial results. Søren ...

Pune Municipal Corporation to create SOPs for RO plants after 19 were sealed due to E. coli contamination, posing public health risks.

Thousands of protesters in Bangladesh took out their anger at exiled former Prime Minister Sheikh Hasina by destroying a ...

Karandikar initially felt unwell after eating vada-pav and drinking water outside and was admitted to Sahyadri Hospital in ...

Analysis of 163 (both confirmed and suspected) cases of GBS has revealed that around 67% or 110 patients undergoing treatment ...

I was treated for GBS when it was relatively unknown, so I want to tell others undergoing treatment to stay positive and have ...